Emergent BioSolutions | EBS - Passivo Circulante





Passivo Circulante Alterar Data
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
Akebia Therapeutics USD 162.94M 29.56M 2025-12
ALKERMES USD 543.44M 69.08M 2025-12
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
Amarin USD 182.23M 3.71M 2025-09
ANI Pharmaceuticals USD 278.11M 7.56M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Coherus Biosciences USD 140.39M 231.91M 2025-12
Emergent BioSolutions USD 651.3M 12.7M 2023-12
Exact Sciences USD 641.15M 56.89M 2025-12
Exelixis USD 405.64M 31.86M 2025-12
Glaxosmithkline GBP 28.68B 8.3B 2025-09
Heron Therapeutics USD 89.71M 168.89M 2025-09
Ionis Pharmaceuticals USD 783M 120.46M 2025-12
Ironwood Pharmaceuticals USD 242.5M 9.98M 2025-09
Lexicon Pharmaceuticals USD 34.84M 75.86M 2025-06
Lonza CHF 3.58B 970M 2024-12
Merck USD 28.63B 2.59B 2025-09
Moderna USD 1.99B 306M 2025-12
Myriad Genetics USD 148M 51.9M 2025-09
Nektar Therapeutics USD 66.34M 5.05M 2025-09
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Pacira USD 120.59M 13.51M 2025-12
Pfizer USD 36.6B 1.13B 2025-09
PTC Therapeutics USD 968.43M 102.18M 2025-12
Sanofi EUR 28.35B 3.76B 2025-12
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
United Therapeutics USD 560.6M 14.3M 2025-12
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12
Xoma USD 28.3M 6.81M 2025-09